FluoGuide A/S (STO:FLUO)
29.50
0.00 (0.00%)
Nov 20, 2026, 5:25 PM CET
FluoGuide Revenue
FluoGuide had revenue of 92.00K DKK in the quarter ending June 30, 2026, with 61.40% growth. This brings the company's total for the last twelve months to 273.00K. In the year 2025, FluoGuide had annual revenue of 220.00K, down -42.86%. That makes FluoGuide the 46,726th largest company in the world by revenue and 767th in Sweden.
Revenue (ttm)
273.00K DKK
Revenue Growth
-42.86%
P/S Ratio
1,192.86
Revenue / Employee
40.75K DKK
Employees
7
Market Cap
482.30M SEK
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 220.00K | -165.00K | -42.86% |
| Dec 31, 2024 | 385.00K | -38.00K | -8.98% |
| Dec 31, 2023 | 423.00K | -6.09M | -93.50% |
| Dec 31, 2022 | 6.51M | -3.10M | -32.27% |
| Dec 31, 2021 | 9.61M | 6.40M | 198.73% |
| Dec 31, 2020 | 3.22M | 3.12M | 3,118.00% |
| Dec 31, 2019 | 100.00K | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cantargia AB | 317.31M |
| Sprint Bioscience AB | 134.13M |
| Oncopeptides AB | 103.50M |
| Intervacc AB | 17.35M |
| Corline Biomedical AB | 13.44M |
| Medivir AB | 8.51M |
| Xspray Pharma AB | 7.19M |
| Infant Bacterial Therapeutics AB | -1.00K |
FluoGuide News
- 2 months ago - FluoGuide Transcript: Investing in Life Science 2026 - Transcripts
- 2 months ago - FluoGuide Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - FluoGuide Quarterly report: Q2 2026 - Filings
- 5 months ago - FluoGuide Earnings Call Transcript: Q1 2026 - Transcripts
- 5 months ago - FluoGuide Quarterly report: Q1 2026 - Filings
- 9 months ago - FluoGuide Earnings Call Transcript: Q4 2025 - Transcripts
- 9 months ago - FluoGuide Annual report: Q4 2025 - Filings
- 9 months ago - FluoGuide Quarterly report: Q4 2025 - Filings